HCV Therapeutic Compounds Reducing Toxicity via Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) therapeutic agents face limitations due to toxicity and side effects, necessitating the development of new HCV therapeutic agents that are more effective and safer for use.
Innovation Solution
A compound of formula (I) or its pharmaceutically acceptable salt, potentially combined with other therapeutic agents like ribavirin analogs, NS3 protease inhibitors, or NS5b polymerase inhibitors, is proposed for the prophylactic or therapeutic treatment of hepatitis C, offering a new approach to inhibit HCV activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current hepatitis C virus (HCV) therapeutic agents are used, then HCV treatment effectiveness is achieved, but toxicity and side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of HCV therapeutic agents through specific molecular substitutions (e.g., introducing heterocyclic rings, adjusting functional groups, and optimizing molecular weight). These structural parameter changes result in compounds that maintain or enhance antiviral activity while reducing toxic side effects, directly resolving the contradiction between treatment effectiveness and safety
Solution Approach 2:
The patent employs composite material principles by designing hybrid molecular structures that combine different functional moieties (e.g., fused ring systems, heterocyclic compounds, and modified nucleoside analogs). These composite molecular architectures enable the drug to achieve multiple functions simultaneously: high antiviral potency, reduced toxicity, and improved pharmacokinetic properties, thereby resolving the contradiction between effectiveness and safety
2Object-affected harmful factors
If new HCV therapeutic agents are developed, then safety is improved, but treatment effectiveness may be compromised
Solution Approach 1:
The patent systematically varies key molecular parameters including molecular weight (optimized range provided), logP values (lipophilicity), and functional group composition to achieve the optimal balance between safety and effectiveness. By carefully adjusting these parameters, the patent ensures that new compounds maintain high antiviral activity while exhibiting improved safety profiles compared to existing therapies
Solution Approach 2:
The patent incorporates feedback mechanisms through iterative structure-activity relationship (SAR) studies and in silico modeling to optimize compound design. Experimental data from preliminary safety and efficacy tests are fed back into the design process to refine molecular structures, ensuring that safety improvements do not compromise treatment effectiveness. This iterative feedback loop enables continuous optimization of both safety and efficacy parameters
Data Source
AI summary
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.